Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.
Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R, Del Sal G. Bisso A, et al. Among authors: cappelletti v. Cell Cycle. 2013 Jun 1;12(11):1679-87. doi: 10.4161/cc.24757. Epub 2013 May 1. Cell Cycle. 2013. PMID: 23656790 Free PMC article.
DESTINY-Breast03 trial: some questions remain.
Di Cosimo S, Apolone G, Cappelletti V, Torri V. Di Cosimo S, et al. Among authors: cappelletti v. Lancet. 2023 May 20;401(10389):1653. doi: 10.1016/S0140-6736(23)00685-2. Lancet. 2023. PMID: 37210116 No abstract available.
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study).
Sepe P, Procopio G, Pircher CC, Basso U, Caffo O, Cappelletti V, Claps M, De Giorgi U, Fratino L, Guadalupi V, Miodini P, De Marco C, Perrucci B, Mennitto A, Santini D, Spina F, Stellato M, de Braud F, Verzoni E. Sepe P, et al. Among authors: cappelletti v. Ther Adv Med Oncol. 2024 Jan 22;16:17588359231217958. doi: 10.1177/17588359231217958. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38264520 Free PMC article.
int-2 oncogene amplification and prognosis in node-negative breast carcinoma.
Fioravanti L, Cappelletti V, Coradini D, Miodini P, Borsani G, Daidone MG, Di Fronzo G. Fioravanti L, et al. Among authors: cappelletti v. Int J Cancer. 1997 Dec 19;74(6):620-4. doi: 10.1002/(sici)1097-0215(19971219)74:6<620::aid-ijc11>3.0.co;2-9. Int J Cancer. 1997. PMID: 9421359 Free article.
miR-30e* is an independent subtype-specific prognostic marker in breast cancer.
D'Aiuto F, Callari M, Dugo M, Merlino G, Musella V, Miodini P, Paolini B, Cappelletti V, Daidone MG. D'Aiuto F, et al. Among authors: cappelletti v. Br J Cancer. 2015 Jul 14;113(2):290-8. doi: 10.1038/bjc.2015.206. Epub 2015 Jun 9. Br J Cancer. 2015. PMID: 26057454 Free PMC article.
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
Ortolan E, Appierto V, Silvestri M, Miceli R, Veneroni S, Folli S, Pruneri G, Vingiani A, Belfiore A, Cappelletti V, Vismara M, Dell'Angelo F, De Cecco L, Bianchi GV, de Braud FG, Daidone MG, Di Cosimo S. Ortolan E, et al. Among authors: cappelletti v. ESMO Open. 2021 Apr;6(2):100086. doi: 10.1016/j.esmoop.2021.100086. Epub 2021 Mar 17. ESMO Open. 2021. PMID: 33743331 Free PMC article.
140 results